SOURCE: Elsevier Business Intelligence
BRIDGEWATER, NJ--(Marketwire - Aug 28, 2012) - EBI invites biopharma's sharpest minds and key decision-makers to join their peers at Therapeutic Area Partnerships (TAP) being held at Westin Copley Place in Boston, MA from November 28th to the 30th. Keynote Speaker Robert S. Langer, MIT professor and founder of over 24 companies, will address "Overcoming the Barriers to Biomedical Breakthroughs from Academia to Industry."
The Keynote Leadership Address will be followed by a Roundtable of Pharma's Business Development Leaders: Barbara Yanni, Vice President and Chief Licensing Officer at Merck & Co., John Delyani, PhD, MBA, Head Therapeutics and Technologies, Strategic Alliances at Novartis Institutes for BioMedical Research, Inc., John McDonald, Vice President of Business Development at Biogen Idec, James A Geraghty, SVP of North American Strategy and Business Development at Genzyme, and Nigel Sheail, Head of Global Business Development & Licensing at Bayer AG.
Since its launch seven years ago, Therapeutic Area Partnerships has made an imprint as the premier biopharmaceutical partnering event of the industry. A highly productive meeting, TAP brings together executives and industry leaders to assess the most promising drug programs available for partnering in Oncology, Cardiovascular/Metabolic Diseases, Neuroscience, Infectious Diseases, Autoimmune/Inflammatory Diseases, and Hot Space, which includes Women's Health, Dermatology, Bone & Muscle Disease, Ophthalmology, Rare Diseases and other high value and niche areas.
Through TAP's premier partnering system, attendees will have the opportunity to hear from and meet some of the industry's most talented biotechnology entrepreneurs and pharmaceutical leaders. Valuable networking opportunities from casual gatherings to one-on-one partnering meetings bring together top-level peers from around the globe to make this one of the industry's most dynamic events.
Every year, TAP's expert-panel hand selects the top 10 projects chosen to present in each therapeutic area based on the likelihood of their success as future products. "Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive neuroscience opportunities the industry has to offer," said David Cassak, Vice President, Content, Windhover Conferences, a division of Elsevier Business Intelligence. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability." Many presenting companies in previous years have gone on to establish major partnerships. View the list of this year's confirmed Top Projects to Watch. Check back frequently, as there are more to come!
This year's agenda, now available online at www.tapartnerships.com, promises to deliver expert analysis of trends and opportunities in licensing and dealmaking, information on emerging biomedical opportunities, strategies for leading, financing and partnering, insights into fast-changing therapeutic areas and much more!
Take full advantage of this opportunity and join a uniquely focused meeting among financing and business development leadership to improve the partnering process and encourage innovative thinking about productivity and dealmaking. Attend TAP this year and walk away with real opportunities for lucrative acquisitions and alliances. For more information, to register, or to hear what past attendees have said about TAP, visit www.tapartnerships.com.
About Elsevier Business Intelligence
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and "The Pink Sheet." For more information, visit: http://www.ElsevierBi.com.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).